










doi:10.101A Pharmacokinetic Study of Plerixafor in Subjects with
Varying Degrees of Renal Impairment
Ronald MacFarland,1 Marjie L. Hard,1 Robert Scarborough,2 Karin Badel,1 Gary Calandra1Plerixafor is a selective antagonist of CXCR4 used for mobilization of hematopoietic stem cells (HSCs) for
autologous stem cell transplantation (SCT) in patients with multiple myeloma (MM) and non-Hodgkin lym-
phoma (NHL). This Phase 1 open-label study in healthy subjects was conducted to evaluate the pharmacoki-
netic characteristics of plerixafor in subjects with renal impairment. All subjects received a single 0.24 mg/kg
subcutaneous dose of plerixafor. Subjects were stratified into 4 cohorts based on creatinine clearance deter-
mined from a 24-hour urine collection: control (.90 mL/min), mild renal impairment (51-80 mL/min), mod-
erate renal impairment (31-50 mL/min), and severe renal impairment (\31 mL/min, not requiring dialysis).
Eleven female subjects (48%) and 12 male subjects (52%), ranging in age from 35 to 73 years, were enrolled.
Plerixafor clearance was reduced in subjects with renal impairment and was positively correlated with creat-
inine clearance. Themean area under the concentration- versus-time curve from time 0 to 24 hours postdose
of plerixafor in subjects with mild, moderate, and severe renal impairment was 7%, 32%, and 39% higher, re-
spectively, than that in subjects with normal renal function. Renal impairment had no effect onmaximal plasma
concentrations. The safety profile was similar among subjects with renal impairment and controls. No renal
impairment–related trends in the incidence of adverse events were apparent. A plerixaflor dose reduction to
160 mg/kg in patients with a creatinine clearance value# 50 mL/min is expected to result in exposure similar
to that in patients with normal to mildly impaired renal function.
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MobilizationINTRODUCTION
Autologous transplantation of peripheral blood he-
matopoietic stem cells (PBSCs) is a widely used strategy
following high-dose chemotherapy for hematologic
malignancies such as multiple myeloma (MM), non-
Hodgkin lymphoma (NHL), Hodgkin disease (HD),
and other cancers, including neuroblastoma [1]. Plerix-
afor (AMD3100) is the first in its class of small mole-
cules that reversibly inhibits the binding of chemokine
stromal cell–derived factor-1a (SDF-1a) to its cognate
receptor CXC chemokine receptor 4 (CXCR4). The
SDF-1a ligand plays an important role in hematopoi-
etic stem cell homing to the bone marrow, as well asGenzymeCorp, Cambridge,Massachusetts; and 2Depart-
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6/j.bbmt.2009.09.003in hematopoietic stem cell maturation. The binding of
SDF-1a to CXCR4 anchors stem cells (CD341 cells)
in the bone marrow (BM) niche. Thus, disruption of
CXCR4 and SDF-1a binding results in the mobiliza-
tion of hematopoietic stem cells into the peripheral
blood. Clinical studies have demonstrated that plerixa-
for administered daily (usually for up to 4 days), or fol-
lowing pretreatment with granulocyte colony-
stimulating factor (G-CSF), increases the number of
PB CD341 cells, resulting in higher CD341 cell yields
as compared to G-CSF alone [2].
Preclinical studies conducted in rats and dogs have
shown that the major route of plerixafor elimination
is urinary, with plerixafor excreted primarily as the
parent molecule, and thus the systemic clearance of
plerixafor is likely to be highly dependent on renal
clearance [3]. Given that plerixafor is eliminated
predominantly unchanged in the urine, renal impair-
ment would be expected to have an effect on the phar-
macokinetics (PK) of plerixafor. Renal impairment is
a common comorbidity in patients with myeloma,
a disease in which plerixafor has demonstrated promise
in mobilizing CD341 cells [4].
The PK of plerixafor were previously examined
following single, s.c. injections in both healthy95
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has exhibited predictable, dose-proportional PK that
is similar in healthy volunteers and cancer patients
[6]. Pretreatment with G-CSF does not affect the PK
of plerixafor [6,7]. The PK-pharmacodynamic rela-
tionship of plerixafor for the mobilization of CD341
cells in the absence of G-CSF pretreatment also has
been demonstrated in healthy volunteers [8].
This Phase 1 study was conducted to evaluate the
PK and safety after a single subcutaneous injection
of 0.24 mg/kg of plerixafor in subjects with varying
degrees of renal impairment compared with subjects
with normal renal function. The results of this
study will be considered in determining whether
dosage adjustments are needed to ensure the safety
and efficacy of plerixafor in patients with renal
impairment.MATERIALS AND METHODS
Study Design
This was a Phase 1, single-dose, opened-label
study conducted at 2 sites in subjects with normal renal
function and various degrees of renal impairment.
The study was conducted in compliance with Good
Clinical Practice guidelines and is registered at
www.clinicaltrials.gov as NCT00445302. All subjects
provided written informed consent to participate in
the study and could withdraw from the study at any
time. The RCRC Institutional Review Board (Austin,
TX) monitored the study.
Inclusion criteria were age 18 to 78 years, white
blood cell count. 3.5 109/L, absolute polymorpho-
nuclear leukocyte count. 2.5 109/L, platelet
count. 125 109/L, serum glutamate oxaloacetate
transaminate\2 times the upper limit of normal
(ULN), serum glutamate pyruvate transaminase\2
ULN, total bilirubin\2 ULN, negative for human
immunodeficiency virus, and provision of signed in-
formed consent. Exclusion criteria included known
sensitivity to plerixafor or any of its components, renal
impairment requiring dialysis, history of kidney trans-
plantation, abnormal electrocardiogramwith clinically
significant disturbance or other conduction abnormal-
ity, positive pregnancy test or lactation in females, and
actual body weight exceeding 175% of the ideal body
mass index.
Patients were stratified into 4 cohorts based on
creatinine clearance values, as measured by 24-hour
urine collection (CLCR). The renal function cohorts
were measured CLCR of 51-80 mL/min (mild renal
impairment cohort), CLCR of 31 to 50 mL/min (mod-
erate renal impairment cohort), CLCR\31 mL/min,
not requiring dialysis (severe renal impairment
cohort), and CLCR. 90 mL/min (control cohort).Drug Administration
Plerixafor was supplied as a 20-mg/mL solution.
A single 0.24-mg/kg dose of plerixafor was adminis-
tered by subcutaneous injection. The patient was
observed for 15-20 minutes after the injection and
remained in the clinic for 10 hours following dose
administration.
Pharmacokinetic Sampling and Assay
Blood samples for PK analysis were collected in
heparinized tubes 30 minutes before plerixafor admins-
tration and at 15 minutes, 30 minutes (6 5 minutes),
and 1, 2, 4, 6, 8, 10 (6 15 minutes), and 24 hours
(6 1 hour) after administration. Urine PK samples
were collected over 3 time intervals at 0-5 hours, 5-
10 hours, and 10-24 hours after administration.
Through a protocol amendment, urine was also col-
lected at 24-48 hours after administration for some sub-
jects in the renal impairment cohorts.
Plasma and urine concentrations were determined
using a validated liquid chromatography and mass
spectrometry (MS) assay (Eurofins AvTech, Kalama-
zoo, MI). In this method, an internal standard (deuter-
ated plerixafor, 5 ng) was added to plasma or urine,
followed by the addition of 2 mg of EDTA. Proteins
were then precipitated by the addition of acetonitrile
acidified with trifluoroacetic acid, followed by vortex-
ing for 5 seconds and microcentrifugation at
12,000 g for 5 minutes. After the supernatants
were transferred to clean tubes, 20 mL of ethylene gly-
col was added, and the samples were vortexed,
followed by evaporation under a stream of nitrogen.
Calibration standards and quality control samples
were prepared by adding plerixafor to blank human
plasma or urine and processed in the same manner as
the subjects’ samples. Following reconstitution in
0.5% trifluoroacetic acid in water, extracts were
analyzed by reverse-phase chromatography (C18 col-
umn; acetonitrile:water gradient; total run duration,
4 minutes) coupled to MS/MS detection (electrospray
interface in positive ion mode). The validated concen-
tration ranges were 5.00-1000 ng/mL for plasma and
1000-10,000 ng/mL for urine.
Pharmacokinetic Analysis
The PK of plerixafor was determined by noncom-
partmental methods using WinNonlin Professional,
version 5.2 (Pharsight, Mountain View, CA). The
maximal concentration (Cmax) and time to Cmax
(Tmax) were determined from direct observation of
the data. The elimination half-life (t1/2) was calcu-
lated as ln2/kel, where kel is the elimination rate
constant, which was determined from the slope of
the ln-linear portion of the concentration versus
time curve using at least 4 nonzero observations dur-
ing the terminal phase (not including Cmax). The area
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quantifiable concentration (AUC0-t) was calculated
using the linear trapezoidal rule. The AUC from
time 0 to infinity (AUC0-inf) was calculated as
AUC0-t1Ct/kel, where Ct is the last quantifiable
concentration at time t. The total plasma clearance
(CL/F) was determined by the dose divided by
AUC0-inf. The volume of distribution (Vz/F) was cal-
culated as dose/(kel AUC0-inf).
The amount of plerixafor excreted in urine (Ae)
was calculated bymultiplying themeasured concentra-
tion by the total volume of urine collected within each
collection interval, and is reported as the percentage
recovery of the dose administered (Fe0-24). Renal clear-
ance (CLr) of plerixafor was calculated as Ae0-24/
AUC0-24, where AUC0-24 is the area under the concen-
tration versus time curve from time 0 to 24 hours
postdose.Safety Assessment
Safety was monitored by clinical and laboratory
evaluations. Laboratory evaluations (ie, blood chemis-
tries, complete blood count with differential, and
coagulation) were conducted at screening, at baseline,
and at 24 and 48 hours postdose. A physical examina-
tion including vital signs and a 12-lead electrocardio-
gram were conducted at screening. All adverse events
(AEs) were ascertained through nonleading question-
ing by the investigator. AEs and serious AEs (SAEs)
were evaluated throughout the study period, and safety
assessments were conducted at 24 and 48 hours post-
dose. AEs were classified by system organ class using
terminology from the Medical Dictionary for Regula-
tory Activities. AEs were graded for intensity using the
modified World Health Organization’s AE grading
scale. The relationship of the AE to plerixafor treat-
ment was determined by the investigator according
to best clinical judgment.Table 1. Summary of Subject Demographic and Baseline Characte
Control (n5 6) Mi
Demographic characteristics











Weight, kg, mean ± SD 92.0 ± 11.73 82
CLCR, mL/min, mean ± SD* 189.2 ± 133.35† 68
*Based on a 24-hour urine collection at screening.
†Outlier value resulting in large SD (455.0 mL/min) that may have been recorde
outlier was 151.2 mL/min, determined using the Cockroft-Gault formula.Statistical Methods
In general, continuous data were summarized
using descriptive statistics (mean, median, and stan-
dard deviation [SD]). Categorical data were summa-
rized by the number and percentage of subjects in
each category. SAS software (SAS Institute, Cary,
NC) was used to perform all statistical analyses.
Linear regression analysis was performed to assess
the relationship between CLCR from 24-hour urine
collection and plerixafor PK parameters. One-way
analysis of variance was used to test for differences
among treatment groups for all PK parameters, with
ln-transformed AUC0-24 andCmax the primary analysis
variables. The differences in means between the re-
nally impaired groups and the normal group, along
with the 90% geometric confidence intervals (CIs),
were calculated. Renal impairment was considered to
have no effect on plerixafor PK if the 90% CI for the
ratio of renal group to normal group least squares
means was contained within the bounds of 80%-
125% for AUC0-24 and 70%-143% for Cmax.RESULTS
Subject Demographics
A total of 23 subjects were enrolled in the study and
treated with plerixafor, including 6 subjects each in the
normal, moderate, and severe renal impairment
cohorts and 5 subjects in the mild renal impairment
cohort (Table 1). The study population was 48%
female (n5 11) and 52% male (n5 12) and ranged
in age from 35 to 73 years (mean, 54.7 years). Of the
23 subjects, 12 were Caucasian (52%), 8 were Afri-
can-American (35%), and 3 were Hispanic/Latino
(13%). Demographic and baseline characteristics
were generally comparable among cohorts with the
exception of age and weight; subjects with normalristics
ld (n5 5) Moderate (n5 6) Severe (n5 6)
.2 ± 14.45 65.0 ± 5.83 55.7 ± 11.98
2 (40) 4 (67) 2 (33)
3 (60) 2 (33) 4 (67)
3 (60) 3 (50) 5 (83)
1 (20) 2 (33) 1 (17)
0 0 0
1 (20) 1 (17) 0
0 0 0
.6 ± 17.90 80.5 ± 16.85 77.3 ± 13.38
.2 ± 6.69 42.0 ± 8.27 17.7 ± 7.20
d incorrectly. The baseline CLCR for the subject who contributed to this
Time (hr)



























Figure 1. Mean plerixafor concentration over time in each cohort. Note that all predose plerixafor concentrations were below the limit of
quantification.
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those in the renal impairment cohorts. There was
a greater proportion of African-American subjects in
the control group than in the renal impairment
cohorts.
Table 1 provides the baselinemeanCLCR based on
the 24-hour urine collection. Two subjects with
borderline CLCR were granted eligibility exemptions
to enroll in the moderate renal impairment cohort
with screening values of 51 mL/min. The baseline
CLCR determined from the 24-hour urine collection
for another subject in the normal cohort was anoma-
lous (455.0 mL/min) and deviated considerably from
the calculated Cockroft-Gault CLCR for this subjectTable 2. Summary of Pharmacokinetic Parameters
Parameter Control (n5 6) M
Tmax, hours Mean ± SD 0.69 ± 0.25
Min, max 0.50, 1.02
Cmax, ng/mL Mean ± SD 980 ± 196
Min, max 812, 1260
Ratio, %*
90% CI*
AUC0-24, ng  h/mL Mean ± SD 5070 ± 979 5
Min, max 3900, 6240
Ratio, %*
90% CI*
AUC0-inf, ng  h/mL Mean ± SD 5220 ± 1050 6
Min, max 3960, 6420
Residual area extrapolated, % Mean ± SD 2.8 ± 1.1
Min, max 1.6, 4.4
T1/2, hours Mean ± SD 4.87 ± 0.56
Min, Max 4.35, 5.74
Vz/F, mL/kg Mean ± SD 332 ± 43.8
Min, Max 261, 376
Cl/F, L/h Mean ± SD 4.38 ± 0.82
Min, Max 3.70, 5.73
Clr, L/h Mean ± SD 3.15 ± 1.70
Min, Max 0.85, 5.83
Fe0-24 (%) Mean ± SD 71.1 ± 42.8
Min, Max 20.5, 150.2
ND indicates not done; AUC, area under the curve; SD, standard deviation.
*Ratios and 90% CIs were calculated from the ln-transformed least squares m(151.2 mL/min). The reason for this anomaly is not
known, but it may have resulted from incorrect record-
ing of the urine volume. This anomalous result was
excluded from the linear regression analysis of the
relationship of PK parameters with CLCR.
Primary Pharmacokinetic Analysis
Mean plasma plerixafor concentration-time profiles
and PK parameters by study group are given in Figure 1
andTable 2, respectively.All predoseplasma concentra-
tions of plerixaforwere below the limit of quantification.
Among all cohorts, plerixafor was absorbed rapidly,
reaching peak concentrations at 30-60 minutes post-
dose. Consistent with the observed increase in systemicild (n5 5) Moderate (n5 6) Severe (n5 6) P value
0.70 ± 0.27 0.54 ± 0.25 0.75 ± 0.27
.5591
0.50, 1.00 0.25, 1.00 0.50, 1.00
739 ± 76.1 936 ± 280 861 ± 193
.2821640, 845 559, 1270 609, 1140
76.3 93.1 87.4
60.0-96.9 74.1-117.0 69.9-109.8
410 ± 1070 6780 ± 1660 6990 ± 1010
.03493970, 6540 4680, 8410 5700, 8050
106.6 132.3 138.8
85.9-132.4 107.7-162.6 112.9-170.55
150 ± 1580 8750 ± 2000 10,200 ± 1440
.00024060, 7910 5570, 10,500 8310, 11,900
10.8 ± 6.3 22.1 ± 5.3 30.6 ± 10.6 ND
1.9, 17.2 15.5, 29.2 17.1, 48.5
7.80 ± 2.15 12.1 ± 2.06 15.8 ± 5.79
<.00014.67, 10.1 9.69, 15.00 9.78, 26.8
433 ± 37.0 512 ± 143 531 ± 145
.2881380, 478 383, 731 390, 793
3.50 ± 1.69 2.42 ± 1.11 1.82 ± 0.38
.00292.43, 6.41 1.75, 4.67 1.52, 2.55
1.64 ± 1.06 0.83 ± 0.40 0.35 ± 0.13
.00280.86, 3.49 0.53, 1.61 0.12, 0.47
40.5 ± 9.6 26.5 ± 5.3 13.6 ± 6.6 ND
26.8, 53.4 19.5, 33.6 4.9, 21.7
ean values.
Table 3. Summary of All AEs by Preferred Term
System Organ Class Preferred Term Control (n5 6) Mild (n5 5) Moderate (n5 6) Severe (n5 6)
Any system organ class Any event 5 (83) 2 (40) 4 (67) 4 (67)
Blood and lymphatic system
disorders
Any event 0 0 0 1 (17)
Leukocytosis 0 0 0 1 (17)
GI disorders Any event 3 (50) 2 (40) 2 (33) 2 (33)
Abdominal distention 0 0 0 1 (17)
Diarrhea 2 (33) 2 (40) 2 (33) 0
Nausea 2 (33) 0 0 1 (17)




Any event 3 (50) 2 (40) 2 (33) 1 (17)
Feeling hot 0 1 (20) 0 0
Injection site erythema 2 (33) 1 (20) 1 (17) 1 (17)
Injection site hemorrhage 0 0 0 1 (17)
Injection site rash 0 1 (20) 0 0
Injection site reaction 1 (17) 1 (20) 1 (17) 0
Investigations Any event 0 0 1 (17) 1 (17)
Red blood cells urine-positive 0 0 1 (17) 0
Urinary sediment present 0 0 1 (17) 0
Urine analysis abnormal 0 0 1 (17) 0
White blood cell count
increased
0 0 0 1 (17)
White blood cells urine-positive 0 0 1 (17) 0
Musculoskeletal and connective
tissue disorders
Any event 2 (33) 0 1 (17) 0
Muscle spasms 2 (33) 0 1 (17) 0
Nervous system disorders Any event 2 (33) 2 (40) 2 (33) 2 (33)
Dizziness 1 (17) 1 (20) 0 0
Dysgeusia 0 0 0 1 (17)
Headache 1 (17) 0 0 0
Hypoesthesia 0 0 0 1 (17)
Paresthesias 1 (17) 1 (20) 2 (33) 0
Sinus headache 0 1 (20) 0 0
Psychiatric disorders Any event 0 1 (20) 0 0
Insomnia 0 1 (20) 0 0
Respiratory, thoracic and
mediastinal disorders
Any event 0 1 (20) 0 0
Hyperventilation 0 1 (20) 0 0
Skin and subcutaneous tissue
disorders
Any event 0 0 0 2 (33)
Erythema 0 0 0 1 (17)
Hyperhidrosis 0 0 0 1 (17)
Pruritus 0 0 0 1 (17)
Vascular disorders Any event 2 (33) 1 (20) 1 (17) 0
Flushing 2 (33) 0 1 (17) 0
Phlebitis 0 1 (20) 0 0
Note. Values are reported as n (%).
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(normal, 4.38 L/h; mild, 3.50 L/h; moderate, 2.42 L/h;
severe, 1.82 L/h) and Clr (control, 3.15 L/h; mild, 1.64
L/h;moderate, 0.83L/h; severe, 0.35L/h)were reduced
in the subjects with renal impairment. In the control co-
hort, approximately 71% of the parent compound was
recovered in the urine by 24 hours postdose, compared
with 40%, 27%, and 14% in themild,moderate, and se-
vere renal impairment cohorts, respectively. For
additional urine collections obtained at 24-48 hours
postdose from subjects enrolled in the mild and severe
cohorts, approximately 4% of the parent compound
was excreted in urine during this period.
Mean values of Cmax were similar among the groups
(normal, 980 ng/mL; mild, 739 ng/mL; moderate, 936
ng/mL; severe, 861 ng/mL). There was no statistically
significant difference among groups for Cmax
(P5 .2821), with the 90% CIs falling mostly within
the range of the equivalence criteria of 0.7-1.43. Con-
versely, a statistically significant difference in AUC0-24among cohorts was observed (P5 .0149). The AUC0-
24 was 106.6%, 132.3%, and 138.8% of the value for
normal renal function in subjects with mild, moderate,
and severe renal impairment, respectively. The upper
limit of the 90% CIs for the moderate and severe renal
impairment groups exceeded the upper limit of the pre-
defined 0.8-1.25 equivalence range.AE
The AE profile in subjects with renal impairment
was very similar to that observed in control subjects,
and there did not appear to be any renal impair-
ment–related trends in terms of the overall incidence
of AEs (Table 3). All AEs were mild to moderate in se-
verity. The most commonly reported AEs were diar-
rhea (26%), injection site erythema (22%), and
paresthesias (17%). AEs considered to be related to
plerixafor were experienced by 15 patients and were
generally mild. The most common AEs related to
100 Biol Blood Marrow Transplant 16:95-101, 2010R. MacFarland et al.plerixafor were injection site reactions (8 patients), GI
effects (7 patients), and nervous system disorders, in-
cluding tingling, paresthesias, and lightheadedness (6
patients). Other AEs related to plerixafor experienced
by 3 or fewer patients included flushing, skin disorders,
muscle spasms, hyperventilation, and leukocytosis.
Importantly, neither the frequency nor the severity
of the observed GI effects and local injection site
reactions were related to the degree of renal impair-
ment. No deaths or SAEs were reported.DISCUSSION
In this Phase 1, opened-label, multicenter renal
impairment study, 23 subjects received a single subcu-
taneous dose of plerixafor (0.24 mg/kg). Subjects were
stratified into 4 cohorts based on their measured
CLCR values: control (CLCR. 90 mL/min), mild
(CLCR5 51-80 mL/min), moderate (CLCR5 31-
50 mL/min), and severe (CLCR\31 mL/min, not
requiring dialysis). The enrollment of 2 subjects with
borderline CLCR (51 mL/min) in the moderate renal
impairment cohort was found not to have a significant
impact on the PK profile of plerixafor when the results
were reanalyzed with these patients included in the
mild cohort. Although differences in demographic
characteristics existed between groups, no effect of
age, race, or sex on plerixafor PK has been reported [9].
Overall, our results indicate that the PK profile of
plerixafor is affected by renal function. In a previous
study, patients with normal renal function and NHL
or MM had a Cmax of 9266 237 ng/mL and an
AUC0-24 of 45006 946 ng  h/mL [6]. These data
are consistent with the estimates in the present study
in subjects with normal renal function (Cmax of
9806 196 ng/mL and AUC0-24 of 50706 979 ng
 h/mL). Statistically significant differences were
observed for PK parameters reflective of elimination
processes (AUC0-24, Cl/F, and T1/2) among renal
function groups. A statistically significant difference
in AUC0-24 among cohorts was observed (P5 .0149).
The AUC0-24 was 106.6%, 132.3%, and 138.8% of
the value for normal renal function in subjects with
mild, moderate, and severe renal impairment, respec-
tively. No differences among cohorts for parameters
associated with the rate of absorption (Tmax and
Cmax) were observed. Consistent with the observed
increase in systemic exposure with increasing renal
dysfunction, mean Cl/F and Clr were reduced in the
subjects with renal impairment. Reduced renal elimi-
nation resulted in an increase in the mean T1/2 from
4.9 hours in subjects with normal renal function to
15.8 hours in those with severe renal impairment.
Although decreased renal function enhanced the ex-
posure to plerixafor in this study, the AE profiles in the
subjects with mild, moderate, and severe renal
impairment were similar to that in the subjects withnormal renal function. There were no trends of increas-
ing frequency or severity of AEs in subjects with
increasing degrees of renal impairment. Plerixafor was
generallywell tolerated,withGIeffects, injection site er-
ythema, and paresthesias the most common AEs. AEs
related to plerixafor were predominantly mild, and
weremost commonly injection site reactions,GI effects,
and nervous system disorders. The indicated adminis-
tration of plerixafor is limited to 4 days of consecutive
dosing, and any potential increase in tissue concentra-
tions is considered unlikely to result in unexpected AEs.
During the development of plerixafor, patients with
renal impairment participating in clinical studies were
dosed with 0.24 or 0.16 mg/kg in various trials [10].
The recommended dose of 0.16 mg/kg for patients
with renal impairment with CLCR# 50 mL/min was
agreed upon with the Food and Drug Administration
[9]. This dose recommendation was based on safety
and efficacy results obtained frommultiple clinical stud-
ies with plerixafor, including a dose escalation study
demonstrating efficient mobilization of CD341 cells
at this dose level [11]. In addition, plasma concentra-
tions following a 0.16 mg/kg dose were simulated using
a population PK model, which predicted similar expo-
sures in patients with moderate to severe renal impair-
ment compared with a reference patient with normal
renal function.
Plerixafor is approved for use with G-CSF for
mobilization and autologous transplantation of hema-
topoietic stem cells in patients with NHL or MM in
the United States. Patients with MM frequently pres-
ent with a serious comorbidity, such as renal impair-
ment. The data presented here should serve as a basis
for future studies to examine the efficacy of plerixafor
in combination with G-CSF for stem cell mobilization
in patients with impaired renal function.ACKNOWLEDGMENTS
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